Literature DB >> 8844089

Molecular-clinical correlations in males with an expanded FMR1 mutation.

S A Merenstein1, W E Sobesky, A K Taylor, J E Riddle, H X Tran, R J Hagerman.   

Abstract

Fragile X syndrome is caused by an expansion of a CGG repeat in the FMR1 gene. The CGG repeat number of the FMR1 mutation and the percentage of cells with methylation of the gene were studied in 218 male patients. Physical and cognitive measurements were also performed. Patients were divided into three groups; those with full mutation and complete methylation (n = 160), those with full mutation and partial methylation (n = 12), and those with a mosaic pattern (n = 46). Statistical comparisons were made between males with the fully methylated full mutation and those with a mosaic pattern. Males having full mutation with complete methylation had the lowest IQ scores and greatest physical involvement. These significant differences were seen only in ages after puberty. CGG repeat length did not correlate with IQ or the physical index score in any group. These findings suggest that a partial production of FMR1 protein may predict milder clinical involvement in some males with fragile X syndrome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8844089     DOI: 10.1002/(SICI)1096-8628(19960809)64:2<388::AID-AJMG31>3.0.CO;2-9

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  65 in total

Review 1.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

Review 2.  MicroRNA dysregulation in neuropsychiatric disorders and cognitive dysfunction.

Authors:  Bin Xu; Pei-Ken Hsu; Maria Karayiorgou; Joseph A Gogos
Journal:  Neurobiol Dis       Date:  2012-03-03       Impact factor: 5.996

Review 3.  Potential therapeutic interventions for fragile X syndrome.

Authors:  Josien Levenga; Femke M S de Vrij; Ben A Oostra; Rob Willemsen
Journal:  Trends Mol Med       Date:  2010-09-21       Impact factor: 11.951

Review 4.  Fragile X: leading the way for targeted treatments in autism.

Authors:  Lulu W Wang; Elizabeth Berry-Kravis; Randi J Hagerman
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

5.  Potential Involvement of Impaired BKCa Channel Function in Sensory Defensiveness and Some Behavioral Disturbances Induced by Unfamiliar Environment in a Mouse Model of Fragile X Syndrome.

Authors:  Maria Isabel Carreno-Munoz; Fabienne Martins; Maria Carmen Medrano; Elisabetta Aloisi; Susanna Pietropaolo; Corentin Dechaud; Enejda Subashi; Guillaume Bony; Melanie Ginger; Abdelmalik Moujahid; Andreas Frick; Xavier Leinekugel
Journal:  Neuropsychopharmacology       Date:  2017-07-19       Impact factor: 7.853

Review 6.  Molecular analysis of FMR1 alleles for fragile X syndrome diagnosis and patient stratification.

Authors:  Daman Kumari; Karen Usdin
Journal:  Expert Rev Mol Diagn       Date:  2020-02-18       Impact factor: 5.225

7.  Physiological arousal in autism and fragile X syndrome: group comparisons and links with pragmatic language.

Authors:  Jessica Klusek; Gary E Martin; Molly Losh
Journal:  Am J Intellect Dev Disabil       Date:  2013-11

Review 8.  Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy.

Authors:  John A Tsiouris; W Ted Brown
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

9.  C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD.

Authors:  Elaine Y Liu; Jenny Russ; Kathryn Wu; Donald Neal; Eunran Suh; Anna G McNally; David J Irwin; Vivianna M Van Deerlin; Edward B Lee
Journal:  Acta Neuropathol       Date:  2014-05-08       Impact factor: 17.088

10.  Autism spectrum disorder in fragile X syndrome: a longitudinal evaluation.

Authors:  R Nick Hernandez; Rachel L Feinberg; Rebecca Vaurio; Natalie M Passanante; Richard E Thompson; Walter E Kaufmann
Journal:  Am J Med Genet A       Date:  2009-06       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.